FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2340893063> ?p ?o ?g. }

• W2340893063 endingPage "1463" @default.
• W2340893063 startingPage "1456" @default.
• W2340893063 abstract "Most hemangiomas are small, harmless birthmarks that appear soon after birth, proliferate for 8 to 18 months, and then slowly regress over the next 5 to 8 years, leaving normal or slightly blemished skin. In rare cases, hemangiomas can endanger vital structures, with a mortality of up to 60 percent. About a third of these life-threatening hemangiomas respond to treatment with corticosteroids, but for the others there is no safe and effective treatment. We evaluated the effects of daily subcutaneous injections of interferon alfa-2a (up to 3 million units per square meter of body-surface area) in 20 neonates and infants with life-threatening or vision-threatening hemangiomas that failed to respond to corticosteroid therapy.In 18 of the 20 patients the hemangiomas regressed by 50 percent or more after an average of 7.8 months of treatment (range, 2 to 13). One infant died of refractory proliferation of a lesion and consumptive coagulopathy. The condition of three other patients who had large hemangiomas associated with consumptive coagulopathies that were unresponsive to conventional therapies stabilized after seven days of treatment with interferon alfa-2a alone. Transient side effects of treatment with interferon alfa-2a included fever, neutropenia (one patient), and skin necrosis (one patient). No long-term toxicity has been observed after a mean follow-up of 16 months.Interferon alfa-2a appears to induce the early regression of life-threatening corticosteroid-resistant hemangiomas of infancy." @default.
• W2340893063 created "2016-06-24" @default.
• W2340893063 creator A5025267270 @default.
• W2340893063 creator A5083281030 @default.
• W2340893063 creator A5088978035 @default.
• W2340893063 date "1992-05-28" @default.
• W2340893063 modified "2023-10-18" @default.
• W2340893063 title "Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy" @default.
• W2340893063 cites W1515391351 @default.
• W2340893063 cites W1539254583 @default.
• W2340893063 cites W1574917816 @default.
• W2340893063 cites W1967191059 @default.
• W2340893063 cites W1982802846 @default.
• W2340893063 cites W1989127158 @default.
• W2340893063 cites W1995232821 @default.
• W2340893063 cites W2006904593 @default.
• W2340893063 cites W2010251779 @default.
• W2340893063 cites W2010476650 @default.
• W2340893063 cites W2011064880 @default.
• W2340893063 cites W2012627695 @default.
• W2340893063 cites W2016901496 @default.
• W2340893063 cites W2018326078 @default.
• W2340893063 cites W2021382762 @default.
• W2340893063 cites W2021677122 @default.
• W2340893063 cites W2021726076 @default.
• W2340893063 cites W2028319272 @default.
• W2340893063 cites W2033766931 @default.
• W2340893063 cites W2047158698 @default.
• W2340893063 cites W2052067965 @default.
• W2340893063 cites W2067262999 @default.
• W2340893063 cites W2079769967 @default.
• W2340893063 cites W2079908159 @default.
• W2340893063 cites W2081727254 @default.
• W2340893063 cites W2104694135 @default.
• W2340893063 cites W2110151585 @default.
• W2340893063 cites W2116830392 @default.
• W2340893063 cites W2147836828 @default.
• W2340893063 cites W2164362851 @default.
• W2340893063 cites W2168016358 @default.
• W2340893063 cites W2169367027 @default.
• W2340893063 cites W2288911208 @default.
• W2340893063 cites W2341474635 @default.
• W2340893063 cites W2412241220 @default.
• W2340893063 cites W4206557022 @default.
• W2340893063 cites W4239435574 @default.
• W2340893063 doi "https://doi.org/10.1056/nejm199205283262203" @default.
• W2340893063 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1489383" @default.
• W2340893063 hasPublicationYear "1992" @default.
• W2340893063 type Work @default.
• W2340893063 sameAs 2340893063 @default.
• W2340893063 citedByCount "1005" @default.
• W2340893063 countsByYear W23408930632012 @default.
• W2340893063 countsByYear W23408930632013 @default.
• W2340893063 countsByYear W23408930632014 @default.
• W2340893063 countsByYear W23408930632015 @default.
• W2340893063 countsByYear W23408930632016 @default.
• W2340893063 countsByYear W23408930632017 @default.
• W2340893063 countsByYear W23408930632018 @default.
• W2340893063 countsByYear W23408930632019 @default.
• W2340893063 countsByYear W23408930632020 @default.
• W2340893063 countsByYear W23408930632021 @default.
• W2340893063 countsByYear W23408930632022 @default.
• W2340893063 crossrefType "journal-article" @default.
• W2340893063 hasAuthorship W2340893063A5025267270 @default.
• W2340893063 hasAuthorship W2340893063A5083281030 @default.
• W2340893063 hasAuthorship W2340893063A5088978035 @default.
• W2340893063 hasBestOaLocation W23408930631 @default.
• W2340893063 hasConcept C121332964 @default.
• W2340893063 hasConcept C141071460 @default.
• W2340893063 hasConcept C142424586 @default.
• W2340893063 hasConcept C187212893 @default.
• W2340893063 hasConcept C203014093 @default.
• W2340893063 hasConcept C2776178377 @default.
• W2340893063 hasConcept C2776694085 @default.
• W2340893063 hasConcept C2777063308 @default.
• W2340893063 hasConcept C2779936836 @default.
• W2340893063 hasConcept C2780191036 @default.
• W2340893063 hasConcept C2781156865 @default.
• W2340893063 hasConcept C2781228144 @default.
• W2340893063 hasConcept C2909179924 @default.
• W2340893063 hasConcept C2909910413 @default.
• W2340893063 hasConcept C71924100 @default.
• W2340893063 hasConcept C87355193 @default.
• W2340893063 hasConceptScore W2340893063C121332964 @default.
• W2340893063 hasConceptScore W2340893063C141071460 @default.
• W2340893063 hasConceptScore W2340893063C142424586 @default.
• W2340893063 hasConceptScore W2340893063C187212893 @default.
• W2340893063 hasConceptScore W2340893063C203014093 @default.
• W2340893063 hasConceptScore W2340893063C2776178377 @default.
• W2340893063 hasConceptScore W2340893063C2776694085 @default.
• W2340893063 hasConceptScore W2340893063C2777063308 @default.
• W2340893063 hasConceptScore W2340893063C2779936836 @default.
• W2340893063 hasConceptScore W2340893063C2780191036 @default.
• W2340893063 hasConceptScore W2340893063C2781156865 @default.
• W2340893063 hasConceptScore W2340893063C2781228144 @default.
• W2340893063 hasConceptScore W2340893063C2909179924 @default.
• W2340893063 hasConceptScore W2340893063C2909910413 @default.
• W2340893063 hasConceptScore W2340893063C71924100 @default.

• next